ERBB2 and breast cancer: The approvals were based primarily on findings from the OlympiAD and EMBRACA randomized open-label trials, which demonstrated significantly improved progression-free survival (PFS) and a manageable adverse event profile in patients with gBRCA1/2mut HER2− advanced breast cancer (ABC) who received olaparib or talazoparib compared with patients who received physician’s choice of chemotherapy (OlympiAD: olaparib versus capecitabine, vinorelbine, or eribulin; EMBRACA: talazoparib versus capecitabine, vinorelbine, eribulin, or gemcitabine) [3, 4].